API | sutimlimab

sutimlimab (Enjaymo) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA

Active Ingredient History

NOW

Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion. Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Complement C1s subcomponent (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (2)

Anemia, Hemolytic, Autoimmune (approved 2022)

Hemolysis (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Anemia, Hemolytic, Autoimmune (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue